Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 1999

View Archived Issues

Priority review status assigned to Rapamune immunosuppressive therapy

Pediatric use of Maxipime approved by the FDA

Roberts and Yuhan enter distribution agreement for Agrylin in Korea

Alza launches Ditropan XL in the U.S.

GABA-A ligands useful for treating CNS disorders

Tachykinin antagonists claimed by HMR for asthma, cough, bronchitis and pain

New series of NHE inhibitors in development at Synthelabo

Enzon initiates phase III trials of PEG-Intron/Rebetol combination therapy for hepatitis C

Improved salts of ACE inhibitors prepared at NicOx

Bayer describes production and use of 2,9-disubstituted purin-6-ones

Schering discloses new leukotriene antagonists particularly useful as dermatological products

Genetics Kenkyusho and Yamanouchi to continue development of joint venture products separately

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Kirin to restart clinical trials of TPO

Clinical trials for Japanese immunosuppressant begin in Europe

KRH-594, a new angiotensin antagonist, evaluated in animal models of hypertension

Genome Therapeutics achieves milestone in asthma alliance with Schering-Plough

Cantab completes acquisition of drug addiction programs from ImmuLogic

New immunomodulator LK-423 possesses unique pharmacological properties

Boehringer Ingelheim seeks E.U. marketing approval for non-CFC respiratory device

Cephalon's narcolepsy treatment launched in Ireland

Moderate drinking reported to protect against ischemic stroke

Ontogen completes phase I study of MDR-modulating compound

Ontogeny enters diabetes research collaboration with Becton Dickinson

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...